Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Barinthus Biotherapeutics plc.BRNS · Entity 9597 | Chief Business Officer | February 03, 2025 | February 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Barinthus Biotherapeutics plc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-02-03 | Direct | 200,000 |
Reported balance
After 2025-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-03 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 5, 2025 16:24 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001828185-25-000010 · wk-form4_1738790649.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 08:55 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 96,500 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-24-001166 · tm241766-3_4seq1.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,500 Underlying: Ordinary Shares · 96,500 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2023 Filed Feb 23, 2023 16:56 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-23-024805 · tm237643-4_4seq1.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2033-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 16:27 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 10,000 | $7.39 | $73,870.00 |
DisclosureSEC source: 0001104659-22-095144 · tm2224672-2_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,209 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.34 - $7.44. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 500 | $4.76 | $2,381.00 |
DisclosureSEC source: 0001104659-22-092959 · tm2223471-4_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,209 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 1,220 | $4.82 | $5,876.37 |
DisclosureSEC source: 0001104659-22-092176 · tm2223471-2_4seq1.xml · nonDerivative · entry 2 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,709 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 2,400 | $4.75 | $11,407.20 |
DisclosureSEC source: 0001104659-22-092176 · tm2223471-2_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,929 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 16:41 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 5,000 | $4.50 | $22,500.00 |
DisclosureSEC source: 0001104659-22-091265 · tm2223471-1_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,329 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 24, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | OtherOrdinary Shares | 100 | $5.87 | $586.80 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · nonDerivative · entry 5 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,329 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 3,090 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · derivative · entry 8 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,180 Underlying: Ordinary Shares · 3,090 shares Expires 2030-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on January 1, 2021. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 2,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · derivative · entry 7 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,317 Underlying: Ordinary Shares · 2,317 shares Expires 2029-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2020. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 1,931 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · derivative · entry 6 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,931 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 8 | $5.28 | $42.24 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · nonDerivative · entry 4 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,229 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These shares were sold to cover the exercise price of options exercised by the Reporting Person. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 3,090 | $0.00 | $1.24 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · nonDerivative · entry 3 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 2,317 | $0.00 | $0.93 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · nonDerivative · entry 2 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 23, 2022 Filed Jul 15, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 1,931 | $0.00 | $0.77 |
DisclosureSEC source: 0001104659-22-080206 · tm2221185-1_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2022 Filed Feb 11, 2022 19:54 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001104659-22-020825 · tm226469-5_4seq1.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 3,090 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · derivative · entry 8 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,270 Underlying: Ordinary Shares · Not disclosed shares Expires 2030-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on January 1, 2021. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3662 to GBP 1.00 on December 31, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 4,636 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · derivative · entry 7 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Ordinary Shares · Not disclosed shares Expires 2029-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2020. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 5,794 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · derivative · entry 6 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,931 Underlying: Ordinary Shares · Not disclosed shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on February 1, 2019. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 102,279 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · derivative · entry 5 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · Not disclosed shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall vest and become exercisable in four equal annual installments, with the first installment vested on October 16, 2018. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 3,090 | $0.00 | $1.24 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · nonDerivative · entry 4 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 4,636 | $0.00 | $1.85 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · nonDerivative · entry 3 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 5,794 | $0.00 | $2.32 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · nonDerivative · entry 2 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 17, 2021 Filed Feb 11, 2022 19:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 102,279 | $0.00 | $40.91 |
DisclosureSEC source: 0001104659-22-020827 · tm226469-7_5seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 16:28 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | PurchaseOrdinary Shares | 100 | $17.00 | $1,700.00 |
DisclosureSEC source: 0001104659-21-062432 · tm2115262-6_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 88,065 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061221 · tm2114558-17_4seq1.xml · derivative · entry 2 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,065 Underlying: Ordinary Shares · 88,065 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 6,054 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061221 · tm2114558-17_4seq1.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Ordinary Shares · 6,054 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.